A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing

NCT00381173 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Ovarian Cancer
Prostate Cancer
Colon Cancer
Renal Cancer

Interventions

DRUG: Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)

Sponsor

Eisai Inc.